March 28, 2024

Drug Delivery Devices Market Set to Surpass US$365 Billion by 2030

The global drug delivery devices market size is forecasted to reach from US$ 225 billion in 2021 to US$ 365 billion by 2030 and is anticipated to grow at compounded annual growth rate (CAGR) of 7.5% from 2021 to 2030, as per reports by market research and consulting organization Precedence Research.

The global drug delivery devices market is segmented By Route of Administratio(Oral, Ocular, Inhalation, Nasal, Injectable, Topical, and Others); By Application: (Cardiovascular, Diabetes, Cancer, Infectious Diseases, and Others); By End Users: (Hospitals, Ambulatory Services, and Home Healthcare)

The report contains 150+ pages with detailed analysis. The base year for the study has been considered 2021, the historic year 2017 to 2020, the forecast period considered is from 2021 to 2030. The drug delivery devices market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit). The report offers exclusive insights to help companies make informed decisions to sustain growth through the assessment period.

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1395

The technological advancements in the medical device manufacturing has led to the development of innovative drug delivery devices that ensures right amount of medicine is administered to the patient at the right time. Moreover, the rising burden of chronic diseases such as diabetes, CVDs, cancer, and COPD is fueling the demand for the drug delivery devices. According to the International Agency for Research on Cancer, in 2020, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe. The global cancer cases are estimated to grow by 47% from 2020 to 2040. It is expected that 28.4 million cases will be recorded in 2040, globally. Moreover, the CVD accounted for around 32% of the global deaths in 2019. The rapid growth of the biopharmaceuticals and development of various drugs that can cure the chronic diseases efficiently fostered the demand for the drug delivery devices across the globe.

Scope of the Drug Delivery Devices Market Report

Report HighlightsDetails
Market SizeUSD 365 Billion by 2030
Growth RateCAGR of 7.5% From 2021 to 2030
Largest MarketNorth America
Fastest Growing MarketAsia Pacific
Segments CoveredRoute of Administration, Application, End User, Region

Competitive Intelligence

The report provides an understanding of the market composition and explains the role of established players and regional contributors. It is essential for the market players to make calculative moves and focus on client acquisition and retention. The detailed company profiles will provide the necessary intelligence to the reader. In order to maintain their share, the market players are focusing on strategies such as cross-border expansion, product differentiation and so on.

Some of the prominent players in the global drug delivery devices market are listed as below:

  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson and Johnson Private Ltd
  • Novartis AG
  • Bayer AG
  • Becton, Dickinson and Company
  • Uniqure NV

Market Share Analysis

The market share analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Market Dynamics

Drivers

  • Increasing demand for non-invasive drug-delivery methods
  • Growing geriatric population and rising ailments
  • Growth in the biologics markets

Restraints

  • High time taken for approval of novel drugs
  • High cases of drug recalls
  • Biocompatibility issues

Opportunities

  • Growing R&D investments
  • Growth in Nanotechnology and technological advancements

Challenges

  • Lack of trained professionals to administer the drugs
  • Inefficiencies in delivering poorly soluble drugs

Recent Developments

3M has re-launched its drug delivery systems through Kindeva, a global contract manufacturing/ development firm focusing on drug delivery projects. This is the newly formed independent entity formed along with Altair post the sales of the drug delivery systems units to Altair Capital Partners for USD 650 Mn. – 4th May 2020

Bayer is venturing into an agreement with Exscientia for the identification and optimization of novel lead structures for potential drug candidates in treating cardiovascular and oncological diseases. – 22nd January 2020

Segments Covered in the Report

By Route of Administration

  • Oral
  • Ocular
  • Inhalation
  • Nasal
  • Injectable
  • Topical
  • Others

By Application

  • Cardiovascular
  • Diabetes
  • Cancer
  • Infectious Diseases
  • Others

By End User

  • Hospitals
  • Ambulatory Services
  • Home Healthcare

Regional Segmentation

– North America (U.S. and Canada)

 – Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)

 – Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)

 – Latin America (Brazil and Rest of Latin America)

– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Why should you invest in this report?

If you are aiming to enter the global drug delivery devices market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for drug delivery devices are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Buy Full Research Report, Click Here@ https://www.precedenceresearch.com/checkout/1395

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Drug Delivery Devices Market 

5.1. COVID-19 Landscape: Drug Delivery Devices Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Drug Delivery Devices Market, By Route of Administration

8.1. Drug Delivery Devices Market, by Route of Administration Type, 2021-2030

8.1.1. Oral

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Ocular

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Inhalation

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Nasal

8.1.4.1. Market Revenue and Forecast (2019-2030)

8.1.5. Injectable

8.1.5.1. Market Revenue and Forecast (2019-2030)

8.1.6. Topical

8.1.6.1. Market Revenue and Forecast (2019-2030)

8.1.7. Others

8.1.7.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Drug Delivery Devices Market, By Application

9.1. Drug Delivery Devices Market, by Application, 2021-2030

9.1.1. Cardiovascular

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Diabetes

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Cancer

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Infectious Diseases

9.1.4.1. Market Revenue and Forecast (2019-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Drug Delivery Devices Market, By End User 

10.1. Drug Delivery Devices Market, by End User, 2021-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Ambulatory Services

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. Home Healthcare

10.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Drug Delivery Devices Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.1.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.3. Market Revenue and Forecast, by End User (2019-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.1.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.1.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.2.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.3. Market Revenue and Forecast, by End User (2019-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.2.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.2.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.2.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.6.3. Market Revenue and Forecast, by End User (2019-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.2.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.7.3. Market Revenue and Forecast, by End User (2019-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.3.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.3. Market Revenue and Forecast, by End User (2019-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.3.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.3.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.3.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.6.3. Market Revenue and Forecast, by End User (2019-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.3.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.7.3. Market Revenue and Forecast, by End User (2019-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.4.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.4.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.4.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.6.3. Market Revenue and Forecast, by End User (2019-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.4.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.7.3. Market Revenue and Forecast, by End User (2019-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.5.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Route of Administration (2019-2030)

11.5.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.5.3. Market Revenue and Forecast, by End User (2019-2030)

Chapter 12. Company Profiles

12.1. Pfizer, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. F. Hoffmann-La Roche Ltd

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Johnson and Johnson Private Ltd

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Novartis AG

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Bayer AG

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Becton, Dickinson and Company

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Uniqure NV

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1395

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

View all posts by Precedence Research →